- Home
- GBFH vs VALN Comparison
GBFH vs VALN Comparison
Compare GBFH & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBFH
- VALN
- Stock Information
- Founded
- GBFH 2007
- VALN 2012
- Country
- GBFH United States
- VALN France
- Employees
- GBFH N/A
- VALN N/A
- Industry
- GBFH
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GBFH
- VALN Health Care
- Exchange
- GBFH NYSE
- VALN Nasdaq
- Market Cap
- GBFH 499.0M
- VALN 542.5M
- IPO Year
- GBFH N/A
- VALN 2021
- Fundamental
- Price
- GBFH $37.42
- VALN $6.00
- Analyst Decision
- GBFH
- VALN Strong Buy
- Analyst Count
- GBFH 0
- VALN 3
- Target Price
- GBFH N/A
- VALN $15.33
- AVG Volume (30 Days)
- GBFH 189.6K
- VALN 14.7K
- Earning Date
- GBFH 04-30-2025
- VALN 08-12-2025
- Dividend Yield
- GBFH N/A
- VALN N/A
- EPS Growth
- GBFH 53.58
- VALN N/A
- EPS
- GBFH 1.40
- VALN N/A
- Revenue
- GBFH $63,591,000.00
- VALN $201,099,222.00
- Revenue This Year
- GBFH N/A
- VALN $18.74
- Revenue Next Year
- GBFH $18.88
- VALN $29.26
- P/E Ratio
- GBFH $26.65
- VALN N/A
- Revenue Growth
- GBFH 36.87
- VALN 21.64
- 52 Week Low
- GBFH $16.75
- VALN $3.62
- 52 Week High
- GBFH $46.00
- VALN $8.66
- Technical
- Relative Strength Index (RSI)
- GBFH N/A
- VALN 52.41
- Support Level
- GBFH N/A
- VALN $5.57
- Resistance Level
- GBFH N/A
- VALN $6.19
- Average True Range (ATR)
- GBFH 0.00
- VALN 0.29
- MACD
- GBFH 0.00
- VALN 0.05
- Stochastic Oscillator
- GBFH 0.00
- VALN 65.60
About GBFH GBANK FINL HLDGS INC
GBank Financial Holdings Inc, through its subsidiary, provides banking services to commercial and consumer customers. The bank accepts deposits from deposit listing services and lends in the local market and national market.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.